ABVC BioPharma, Inc. (NasdaqCM: ABVC)
Health Care · Biotechnology · US
$0.92
-8.21% today · -69.4% 1Y
ABVC BioPharma, Inc. (NasdaqCM: ABVC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $23.80M and employs 18 people.
Over the last twelve months the share price has lost 69.4%, trading between 0.71 and 3.07.
Tweenvest scores ABVC BioPharma, Inc. across four factors: quality 29/100, value 49/100. Its strongest factor is value.
ABVC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $23.80M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.29
- Dividend yield
- —
- Beta (5Y)
- 0.51
- 52-week high
- $3.07
- 52-week low
- $0.71
- Avg volume (3M)
- —
- Shares outstanding
- 25.92M
- Employees
- 18
- Next earnings
- —
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
- ISIN
- US00091F3047
- Listed since
- Nov 10, 2004
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Ribomic Inc.TSE: 4591 | $24.36M | ¥68.00 | -4.23% |
| Polyrizon Ltd.NasdaqCM: PLRZ | $24.29M | $10.00 | +11.26% |
| Shuttle Pharmaceuticals Holdings, Inc.NasdaqCM: SHPH | $24.20M | $5.08 | -4.69% |
| Eutilex.Co.,LtdKOSDAQ: A263050 | $24.14M | ₩— | — |
| Xbrane Biopharma AB (publ)OM: XBRANE | $23.72M | Skr11.40 | -18.28% |
| GeneMatrix Inc.KOSDAQ: A109820 | $23.69M | ₩1,549.00 | -9.94% |
| Transgenic Group Inc.TSE: 2342 | $23.63M | ¥224.00 | -4.27% |
| Evaxion A/SNasdaqCM: EVAX | $23.60M | $2.83 | -7.82% |
Figures last refreshed Oct 18, 2026.